Long-term mortality after PCI in patients with diabetes mellitus: Results from the Swedish Coronary Angiography and Angioplasty Registry

EuroIntervention

Volumn 5, Issue 8, 2010, Pages 891-897

  Norhammar, Anna ^a   Lagerqvist, Bo ^b   Saleh, Nawsad ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute coronary syndrome; Diabetes mellitus; Long term prognosis; Mortality; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR; INSULIN; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTION; RISK FACTOR; SEX DIFFERENCE; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; SWEDEN; ANGIOCARDIOGRAPHY; INSTRUMENTATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; REGISTER; RISK ASSESSMENT; STENT; SURVIVAL; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STENTS; SURVIVAL ANALYSIS; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956201361     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV5I8A152     Document Type: Article

References (25)

1. Norhammar A, Lindback J, Rydén L, Wallentin L, Stenestrand U. Improved but still high short and long-term mortality after myocardial infarction in patients with diabetes mellitus. A time trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart. 2007;93:1577-1583.
2. Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Rydén L, Wallentin L. Diabetes Mellitus: The major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol. 2004;43:85-91.
3. Norhammar A, Malmberg K, Rydén L, Tornvall P, Stenestrand U, Wallentin L, for the Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA). Under utilisation of evidence- based treatment partial explanation for the unfavorable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J. 2003;24:838-844.
4. Lagerqvist Bo, Husted S, Kontny F, Ståhle E, Swahn E, Wallentin L and the Fast Revascularisation during InStability in Coronary artery disease (FRISC-II) Investigators. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet. 2006;368:998-1004.
5. The BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335:217-225.
6. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for Percutaneous Coronary Interventions. Eur Heart J. 2005;26:804-847.
7. Iijima R, Byrne RA, Ndrepepa G, Braun S, Mehilli J, Berger PB, Schömig A, Kastrati A. Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. Heart. 2009;95:107-12.
8. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A. Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006;295:1531-8.
9. Ndrepepa G, Kastrati A, Mehilli J, Neumann FJ, ten Berg J, Bruskina O, Dotzer F, Seyfarth M, Pache J, Dirschinger J, Berger PB, Schömig A. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. Eur Heart J. 2008;29:455-61.
10. Patti G, Nusca A, Di Sciascio G. Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol. 2008;15;102:1328-34.
11. Nikolsky E, Gruberg L, Patil CV, Roguin A, Kapeliovich M, Petcherski S, Boulos M, Grenadier E, Amikam S, Linn S, Markiewicz W, Beyar R. Percutaneous coronary interventions in diabetic patients: is complete revascularization important? J Invasive Cardiol. 2004;16:102-6.
12. Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, Buse JB, Cohen DJ, Mahoney E, Sleeper L, King P, Domansi M, McKinlay S, Fuster V. Design of the Future REvascualrization Evaluation in patients with Diabetes mellitus: optimal management of multivessel disesase (FREEDOM) trial. Am Heart J. 2008;155:215-23.
13. Serruys PW, Ong ATL, van Herwerden LA, Sousa EJ, Jatene A, Bonnier JJR M, Shcönberger JPMA, Buller N, Bonser R, Disco C, Backx B, Hugenholtz PG, Firth BG, Unger F. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease. The final analysis of Arterial Revascularization Therapies Study (ARTS) Randomized Trial. J Am Coll Cardiol. 2005;46:575-81. (Pubitemid 41132680)
14. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW. SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961-72.
15. Diedrichs H, Pfister R, Hagemeister J, Müller-Ehmsen J, Frank KF, Höpp HW, Erdmann E, Schneider CA. An increase in HbA1c after percutaneous coronary intervention raises the risk for restenosis in patients without Type 2 diabetes mellitus. Diabet Med. 2008;25;:228-31. (Pubitemid 351293394)
16. Saleh N, Tornvall P. Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis. Atherosclerosis. 2007;195:374-8. (Pubitemid 350087945)
17. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000;343:1139-47.
18. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006;47:C19-31.
19. Gresele P, Guglielmini G, De Angelis M Ciferri S, Ciofetta M, Falcinelli E, Lalli C, Ciabattoni G, Davì G, Bolli GB. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol. 2003;41:1013-20. (Pubitemid 36315547)
20. Yngen M, Norhammar A, Hjemdahl P, Wallén NH. Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diab Vasc Dis Res. 2006;3:52-6. (Pubitemid 43877254)
21. Eibl N, Krugluger W, Streit G Schrattbauer K, Hopmeier P, Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest. 2004;34:205-09. (Pubitemid 38406635)
22. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007;115;708-716. (Pubitemid 46294761)
23. Angiolillo DJ, Bernardo E, Ramirez C, Costa MA, Sabaté M, Jimenez- Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Bass TA, Macaya C, Fernandez-Ortiz A. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol. 2006;48:298-304. (Pubitemid 44026661)
24. Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernández-Antolin R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Guzman LA, Bass TA, Macaya C, Fernandez- Ortiz A. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50:1541-1547. (Pubitemid 47532327)
25. Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann- Vague V. Silent myocardial ischaemia in patients with diabetes. Who to screen. Diabetes Care. 1999;22:1396-1400.